Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: A retrospective single-center study

Chemotherapy

Volumn 58, Issue 3, 2012, Pages 225-232

  Woo, Sang Myung ^a   Lee, Woo Jin ^a   Han, Sung Sik ^a   Park, Sang Jae ^a   Kim, Tae Hyun ^a   Koh, Young Hwan ^a   Kim, Hyun Bum ^a   Hong, Eun Kyung ^a   Park, Joong Won ^a   Kim, Chang Min ^a  

^a National Cancer Center   (South Korea)

Author keywords

Capecitabine; Cholangiocarcinoma; Cisplatin

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; CISPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BILIARY TRACT CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER THERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; BILE DUCTS, INTRAHEPATIC; BILIARY TRACT NEOPLASMS; CA-19-9 ANTIGEN; CHOLANGIOCARCINOMA; CISPLATIN; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; GALLBLADDER NEOPLASMS; HUMANS; INJECTIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84864103251     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000339499     Document Type: Article

References (34)

1. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM: Biliary tract cancers. N Engl J Med 1999;341:1368-1378.
2. Shaib Y, El-Serag HB: The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004;24:115-125. (Pubitemid 38738341)
3. Shin HR, Jung KW, Won YJ, Park JG: 2002 Annual Report of the Korea Central Cancer Registry, based on registered data from 139 hospitals. Cancer Res Treat 2004;36:103-114.
4. Patel T: Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002;2:10.
5. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H: Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002;51(suppl 6):VI1-VI9. (Pubitemid 35216840)
6. Miyakawa S, Ishihara S, Horiguchi A, Takada T, Miyazaki M, Nagakawa T: Biliary tract cancer treatment:5, 584 results from the biliary tract cancer statistics registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg 2009;16:1-7.
7. Eckel F, Schmid RM: Emerging drugs for biliary cancer. Expert Opin Emerg Drugs 2007;12:571-589. (Pubitemid 350193096)
8. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-1281.
9. Patt YZ, Hassan MM, Lozano RD, Waugh KA, Hoque AM, Frome AI, Lahoti S, Ellis L, Vauthey JN, Curley SA, Schnirer II, Raijman I: Phase II trial of cisplatin, interferon alpha-2B, doxorubicin, and 5-fluorouracil for biliary tract cancer. Clin Cancer Res 2001;7:3375-3380. (Pubitemid 33069968)
10. Eckel F, Schmid RM: Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007;96:896-902. (Pubitemid 46452283)
11. Ishitsuka H: Capecitabine: Preclinical pharmacology studies. Invest New Drugs 2000;18:343-354.
12. Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, Vauthey JN, Ellis LM, Schnirer II, Wolff RA, Charnsangavej C, Brown TD: Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 2004;101:578-586. (Pubitemid 38970609)
13. Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, Nematollahi M, Pond GR, Zhang J, Moore MJ: Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005;23:2332-2338. (Pubitemid 46218726)
14. Riechelmann RP, Townsley CA, Chin SN, Pond GR, Knox JJ: Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer 2007;110:1307-1312. (Pubitemid 47435603)
15. Hong YS, Lee J, Lee SC, Hwang IG, Choi SH, Heo JS, Park JO, Park YS, Lim HY, Kang WK: Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. Cancer Chemother Pharmacol 2007;60:321-328. (Pubitemid 46944586)
16. Kim TW, Chang HM, Kang HJ, Lee JR, Ryu MH, Ahn JH, Kim JH, Lee JS, Kang YK: Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol 2003;14:1115-1120. (Pubitemid 36950177)
17. Torzilli G, Makuuchi M, Ferrero A, Takayama T, Hui AM, Abe H, Inoue K, Nakahara K: Accuracy of the preoperative determination of tumor markers in the differentiation of liver mass lesions in surgical patients. Hepatogastroenterology 2002;49:740-745. (Pubitemid 34615340)
18. Qin XL, Wang ZR, Shi JS, Lu M, Wang L, He QR: Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA. World J Gastroenterol 2004;10:427-432. (Pubitemid 38208101)
19. Ali CW, Kaye TF, Adamson DJ, Tait IS, Polignano FM, Highley MS: CA19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma. J Gastrointest Cancer 2007;38:108-114.
20. Kim ST, Park JO, Lee J, Lee KT, Lee JK, Choi SH, Heo JS, Park YS, Kang WK, Park K: A phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer 2006;106:1339-1346. (Pubitemid 43363912)
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
22. Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, Linne T, Svensson C: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996;7:593-600. (Pubitemid 26285639)
23. Rao S, Cunningham D, Hawkins RE, Hill ME, Smith D, Daniel F, Ross PJ, Oates J, Norman AR: Phase III study of 5FU, etoposide and leucovorin (fFELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer 2005;92:1650-1654. (Pubitemid 40756474)
24. Kim MJ, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ: Gemcitabinebased versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study. BMC Cancer 2008;8:374.
25. Hollebecque A, Bouche O, Romano O, Scaglia E, Cattan S, Zerbib P, Heurgue A, Lagarde S, Mariette C, Triboulet JP, Pruvot FR, Hebbar M: Experience of gemcitabine plus oxaliplatin chemotherapy in patients with advanced biliary tract carcinoma. Chemotherapy 2010;56:234-238.
26. Chung MJ, Kim YJ, Park JY, Bang S, Song SY, Chung JB, Park SW: Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer. Chemotherapy 2011;57:236-243.
27. Woo SM, Ryu JK, Lee SH, Yoo JW, Park JK, Kim YT, Jang JY, Kim SW, Kang GH, Yoon YB: Recurrence and prognostic factors of ampullary carcinoma after radical resection: Comparison with distal extrahepatic cholangiocarcinoma. Ann Surg Oncol 2007;14:3195-3201. (Pubitemid 47594288)
28. Nehls O, Oettle H, Hartmann JT, Hofheinz RD, Hass HG, Horger MS, Koppenhofer U, Hochhaus A, Stieler J, Trojan J, Gregor M, Klump B: Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 2008;98:309-315. (Pubitemid 351161262)
29. Briggs CD, Neal CP, Mann CD, Steward WP, Manson MM, Berry DP: Prognostic molecular markers in cholangiocarcinoma: a systematic review. Eur J Cancer 2009;45:33-47.
30. Boeck S, Haas M, Laubender RP, Kullmann F, Klose C, Bruns CJ, Wilkowski R, Stieber P, Holdenrieder S, Buchner H, Mansmann U, Heinemann V: Application of a time-varying covariate model to the analysis of CA19-9 as serum biomarker in patients with advanced pancreatic cancer. Clin Cancer Res 2010;16:986-994.
31. Koom WS, Seong J, Kim YB, Pyun HO, Song SY: CA19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009;73:1148-1154.
32. Lee J, Lim do H, Kim S, Park SH, Park JO, Park YS, Lim HY, Choi MG, Sohn TS, Noh JH, Bae JM, Ahn YC, Sohn I, Jung SH, Park CK, Kim KM, Kang WK: Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012;30:268-273.
33. Evans TR, Pentheroudakis G, Paul J, McInnes A, Blackie R, Raby N, Morrison R, Fullarton GM, Soukop M, McDonald AC: A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophagogastric adenocarcinoma. Ann Oncol 2002;13:1469-1478.
34. Clayton AJ, Mansoor AW, Jones ET, Hawkins RE, Saunders MP, Swindell R, Valle JW: A phase II study of weekly cisplatin and gemcitabine in patients with advanced pancreatic cancer: is this a strategy still worth pursuing? Pancreas 2006;32:51-57. (Pubitemid 41803647)